Table 1. Characteristics of the... | American Society of Hematology

Table 1.

Characteristics of the retrospective cohort (n = 1292)

	All patients		Less intensive (n = 293)		Intensive (n = 999)
	n	%	n	%	n	%
Age, y
18-49	299	23	4	1	295	30
50-59	264	20	11	4	253	25
60-64	211	16	22	8	189	19
65-69	210	16	60	20	150	15
70-74	132	10	69	24	63	6
75-79	110	9	74	25	36	4
80-89	66	5	53	18	13	1
Augmented HCT-CI
0-1	158	12	19	6	139	14
2-3	339	26	46	16	293	29
4-5	292	23	64	22	228	23
≥6	350	27	101	34	249	25
Missing	153	12	63	22	90	9
ELN 2017 cytogenetic risk
Favorable	225	17	19	6	206	21
Intermediate	609	47	132	45	477	48
Adverse	405	31	130	44	275	28
Missing	53	4	12	4	41	4
KPS
>70	789	61	191	65	598	60
≤70	256	20	88	30	168	17
Missing	247	19	14	5	233	23
AML-CM
≤3	172	13	2	1	170	17
4-6	354	27	54	18	300	30
7-9	314	24	70	24	244	24
≥10	261	20	97	33	164	16
Missing	191	15	70	24	121	12
Diagnosis
Newly diagnosed AML	1292	100	293	100	999	100

	All patients		Less intensive (n = 293)		Intensive (n = 999)
	n	%	n	%	n	%
Age, y
18-49	299	23	4	1	295	30
50-59	264	20	11	4	253	25
60-64	211	16	22	8	189	19
65-69	210	16	60	20	150	15
70-74	132	10	69	24	63	6
75-79	110	9	74	25	36	4
80-89	66	5	53	18	13	1
Augmented HCT-CI
0-1	158	12	19	6	139	14
2-3	339	26	46	16	293	29
4-5	292	23	64	22	228	23
≥6	350	27	101	34	249	25
Missing	153	12	63	22	90	9
ELN 2017 cytogenetic risk
Favorable	225	17	19	6	206	21
Intermediate	609	47	132	45	477	48
Adverse	405	31	130	44	275	28
Missing	53	4	12	4	41	4
KPS
>70	789	61	191	65	598	60
≤70	256	20	88	30	168	17
Missing	247	19	14	5	233	23
AML-CM
≤3	172	13	2	1	170	17
4-6	354	27	54	18	300	30
7-9	314	24	70	24	244	24
≥10	261	20	97	33	164	16
Missing	191	15	70	24	121	12
Diagnosis
Newly diagnosed AML	1292	100	293	100	999	100